INTRODUCTION

Human immunodeficiency virus-1 (HIV-1) infection can
cause HIV-associated neurocognitive disorders (HAND), a set of conditions ranging from subtle neuropsychological impairments to HIV-associated dementia (HAD), the most severe form of HAND (1, 2) . The introduction of highly active antiretroviral therapies (ART/HAART) has effectively increased the life span of people living with HIV-1/AIDS. However, recent epidemiological studies indicate that the prevalence of HAND with some form of neurocognitive impairment appears to be increasing up to 50% of HIVinfected individuals despite access to ART (3, 4) . Furthermore, the incidence of Alzheimer's disease (AD)-like neurocognitive problems and neuropathological features of AD in older HIV-1-infected patients is increasing as HIV infection has become a chronic and manageable condition under ART (5, 6) . AD, primarily affecting the population over the age of 60, is the most common and still incurable form of dementia (7) . AD is primarily an auto "proteopathic" neurodegenerative 102 disease initiated in neurons by misfolding and aggregation of two specific proteins, Aβ and Tau, which in later stages of disease form the characteristic lesions of Aβ-containing senile plaques, usually surrounded by reactive astrocytes, activated microglia and dystrophic neuritis, and intracellular neurofibrillary tangles (8) . Inflammation plays a prominent role in AD but it appears to be secondary to Aβ and Tau accumulation (9) . These major pathogenetic mechanisms of AD, in concert, lead to neocortical and hippocampal atrophy, memory dysfunction and decline of cognition in AD.
HIV-1 transactivator of transcription protein (Tat), a viral nonstructural protein of 86~104 amino acids in length, is the product of two exons and contributes to the induction of viral and cellular genes (10) . Tat can be secreted by infected macrophages and microglia, and transported across the blood-brain barrier (11) has been detected in brain of patients with HAD (12), implicating a possible role in the progression of HAND. Furthermore, some HIV-positive patients exhibiting the HAND phenotype with an increase in Aβ deposition (13, 14) or increased levels of Tau and phosphorylated Tau (pTau) protein (15, 16) 
MATERIALS AND METHODS
Materials
Anti-Tau (mouse monoclonal antibody clone Tau-5), which can identify total Tau, was purchased from Santa Cruz 
Preparation of Tat
Biologically active recombinant HIV-1 Tat1-86 of (HIV- 
Hippocampal slice cultures
All experimental procedures were performed using protocols approved by the Animal Care Committee of the Ewha Medical Research Institute. Hippocampal slice cultures were prepared from 10-day-old Sprague-Dawley rat pups (Harlan, Indianapolis, IN, USA) as previously described (17, 18) . In hippocampal slices, cells, synapses, and neuronal connectivity mature in parallel with their counterparts in vivo (19) . Thus, these preparations are deemed appropriate for studies of prolonged pharmacological treatment and recovery without blood flow, which would be difficult to perform in an intact animal system.
Experimental treatments
Treatments were initiated at 10 days post-dissection. All reagents were added to serum-free medium (no horse serum) equilibrated at 37℃ in 5% CO 2 prior to addition to the slices.
Slices were stimulated with Tat1-86 (1 μM) for 3 days as previously described (18) . Vehicles were prepared identically to experimental treatments but did not contain Tat. At the indicated time after treatment initiation, the slices were rinsed twice in 1x PBS, then harvested via the removal of Millicell membrane inserts after sample freezing on dry ice.
They were then processed for immunoblotting as described below. The culture media were also collected to analyze the level of Aβ release.
Enzyme-Linked Immunosorbent Assay (ELISA)
The levels of Aβ1-40 in the culture media were determined using commercially available ELISA kit in accordance with the manufacturer's protocol. In short, 100 μl of sample was added into the precoated plate and was incubated overnight at 4℃. After washing each well of the precoated plate with washing buffer, 100 μl of labeled antibody solution was added and the mixture was incubated for 1 hr at 4℃ in the dark. After washing, chromogen was added and the mixture was incubated for 30 mins at room temperature in the dark. After the addition of stop solution, the resulting color was assayed at 450 nm using a microplate absorbance reader.
Polyacrylamide gel electrophoresis and western blotting
Western blotting was conducted as recently described (17, 18) . Whole cell extracts obtained and equal quantities of Densitometric values were normalized versus β-actin.
Statistical analysis
Data were expressed as the mean ± SEM of the indicated numbers of experimental replicates. Differences among groups were evaluated for statistical significance using oneway ANOVA with a Student's t test. Statistical significance was considered to be p < 0.05. (Fig. 1C) .
RESULTS AND DISCUSSION
Accumulating
Importantly, Tat1-86 treatment resulted in a prominent increase in the level of pTau identified by AT8 antibody, which binds to abnormally hyperphosphorylated Tau in the hippocampus ( Fig. 2A and C) , compared with the vehicletreated samples under the same experimental conditions ( Fig.   2A and B 
